Intracranial Tumor Resection Surgery
Conditions
Interventions
Experimental Group One:After anesthesia induction and before the start of surgery, a loading dose of 0.75 mg tegileridine will be administered, followed by a patient-controlled analgesia (PCA) bolus o
Experimental Group Two:After anesthesia induction and before the start of surgery, a loading dose of 1 mg tegileridine will be administered, followed by a patient-controlled analgesia (PCA) bolus of 0
Experimental Group Three:After anesthesia induction and before the start of surgery, administer a loading dose of 0.75 mg tegileridine, followed by a patient-controlled analgesia (PCA) bolus of 0.05 m
Experimental Group Four:
After anesthesia induction and before the start of surgery, administer a loading dose of 1 mg tegileridine, followed by a patient-controlled analgesia (PCA) bolus of 0.05 mg p
Control Group:
After anesthesia induction and before the start of surgery, administer a loading dose of 0.3 µg sufentanil, followed by a patient-controlled analgesia (PCA) bolus of 0.2 µg per injectio
Sponsors
The Second People's Hospital of Guiyang
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1. Age> = 18 years old and < 65 years old, gender is not limited; 2. Patients with American Society of Anesthesiologists score (ASA score) grade I-II; 3. Those who have undergone craniotomy for the first time to resect intracranial tumors and have no history of radiotherapy and chemotherapy in the past; 4. Preoperative MRI showed that the tumor diameter was =40 mm; 5. Preoperative Mini-Mental State Scale (MMSE) score= 23 points; 6. Subjects or their legal representatives are able to sign the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1. Glasgow Coma Scale (GCS) score of <15; 2. Patients with other malignant tumors; 3. Pregnancy or lactation; 4. Patients with serious underlying diseases of heart, lung, liver, kidney and other organs; 5. Patients with mental disorders who are unable to cooperate with the completion of intraoperative anesthesia assessment; 6. Patients with severe respiratory depression (oxygen saturation <90%); 7. Patients with acute or severe bronchial asthma without vital signs monitoring or vital resuscitation equipment; 8. Known or suspected gastrointestinal obstruction, including patients with paralytic intestinal obstruction; 9. Patients who are allergic to opioids and any of the ingredients of this product are prohibited; 10. Recent frequent use of analgesics, tolerance to opioids or physical dependence; 11. Participated in other clinical trials within 4 weeks before surgery; 12. Those who are considered unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The sum of pain intensity differences within 24 hours after administration (SPID24) is defined as the time-weighted sum of pain intensity within 24 hours after the start of treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The sum of pain intensity differences within 4 hours (SPID4), 8 hours (SPID8), 12 hours (SPID12), 16 hours (SPID16), 20 hours (SPID20), and 48 hours (SPID48) after administration.; | — |
Countries
China
Contacts
Public ContactFang Hua
The Second People's Hospital of Guiyang
Outcome results
None listed